StreetInsider.com News Articles

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

Fri, 10 Jul 2026 08:30:00 -0400

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage & Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle & Vision Summit, taking place July 16th in Boston, Massachusetts. The panel discussion will be held from 3:10 p.m. to 3:50 p.m. ET.

For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

Fri, 10 Jul 2026 08:30:00 -0400

For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

Fri, 10 Jul 2026 08:30:00 -0400

For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

Fri, 10 Jul 2026 08:30:00 -0400

For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

Fri, 10 Jul 2026 08:30:00 -0400

For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

Fri, 10 Jul 2026 08:30:00 -0400

For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

Fri, 10 Jul 2026 08:30:00 -0400

For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

Fri, 10 Jul 2026 08:30:00 -0400

For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to

Raymond James Starts Alpha Cognition Inc (ACOG) at Outperform

Fri, 10 Jul 2026 06:05:46 -0400

Raymond James analyst Ryan Deschner initiates coverage on Alpha Cognition Inc (NASDAQ: ACOG) with a Outperform rating and a price target of $20.00.

The analyst comments "We are initiating coverage of Alpha Cognition (ACOG), with an Outperform rating and $20 price target. ACOG markets Zunveyl (benzgalantamine), a prodrug of FDA-approved galantamine, which is indicated for the treatment of mild-to-moderate dementia in patients with Alzheimer’s disease (AD). Zunveyl’s prodrug format is designed to mitigate gastrointestinal (GI) and other adverse events (AEs) that are a primary source of discontinuation for the most commonly prescribed class of AD drugs: acetylcholinesterase (AChE) inhibitors. Since launch

Raymond James Starts Alpha Cognition Inc (ACOG) at Outperform

Fri, 10 Jul 2026 06:05:46 -0400

Raymond James analyst Ryan Deschner initiates coverage on Alpha Cognition Inc (NASDAQ: ACOG) with a Outperform rating and a price target of $20.00.

Form SCHEDULE 13G/A Alpha Cognition Inc. Filed by: Opaleye Management Inc.

Mon, 29 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260629/26706385.html

Form SCHEDULE 13G/A Alpha Cognition Inc. Filed by: Opaleye Management Inc.

Mon, 29 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260629/26706385.html

Form 4 Alpha Cognition Inc. For: Jun 25 Filed by: Opaleye Management Inc.

Mon, 29 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260629/26706388.html

Form 4 Alpha Cognition Inc. For: Jun 25 Filed by: Opaleye Management Inc.

Mon, 29 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260629/26706388.html

Form 8-K Alpha Cognition Inc. For: Jun 16

Tue, 23 Jun 2026 10:36:00 -0400

si-local-file:///var/storage/secattach/20260623/26677685.html

Form 8-K Alpha Cognition Inc. For: Jun 16

Tue, 23 Jun 2026 10:36:00 -0400

si-local-file:///var/storage/secattach/20260623/26677685.html

Alpha Cognition names Dr. Robert Wills as board chairman

Tue, 23 Jun 2026 08:30:38 -0400

Alpha Cognition Inc. (Nasdaq: ACOG) has elected Dr. Robert Wills as Chairman of the Board, succeeding Len Mertz, who has retired from the board after serving as chairman since 2021, according to a press release from the biopharmaceutical company.

Dr. Wills has served on Alpha Cognition's board since 2025 and currently chairs the Governance and Nominating Committee while also serving on the Audit Committee. He also serves as Chairman of the Board of Milestone Pharmaceuticals Inc. (Nasdaq: MIST) and as a board member at Parion Sciences Inc.